Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia
Dennis Marjoncu,(1) PharmD, BCOP, and Benjamin Andrick,(2) PharmD, BCOP
From (1)Methodist University Hospital, Memphis, Tennessee; (2)Geisinger Medical Center, Danville, Pennsylvania
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Dennis Marjoncu, PharmD, 1265 Union Avenue, Memphis, TN 38104.
J Adv Pract Oncol 2020;11(1):104–108 |
© 2020 Harborside™
Acute myeloid leukemia (AML) is the most common adult leukemia, with an overall poor prognosis. New agents targeting various receptors may improve treatment outcomes and overall survival. FMS-like tyrosine kinase 3 (FLT3) is a targetable mutation occurring in one third of AML patients. It contributes to increased tumor proliferation and decreased cellular differentiation, ultimately conferring a poor overall prognosis. Among patients with FLT3-positive relapsed/refractory AML, outcomes are particularly dismal. Gilteritinib is a novel, second-generation FLT3 inhibitor approved by the U.S. Food & Drug Administration (FDA) for the treatment of relapsed/refractory AML with an FLT3 mutation as detected by an FDA-approved test.
For access to the full length article, please sign in